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fractions) Adaptive Radiotherapy (ART) approach delivering a 
concomitant boost to the MRI-based residual tumour during 
the last 6 fractions. 
Materials and Methods: T3/T4N0 or N+ rectal 
adenocarcinoma patients (pts) were enrolled in an 
observational trial. Concomitant chemotherapy consisted of 
Oxaliplatin 100mg/m2 on days -14, 0, +14, and 5-FU 
200mg/m2/day from day -14 to the end of radiotherapy (day 
0 is the start of radiotherapy). Radiotherapy consisted in the 
delivery of 41.4Gy in 18 fractions (fr) (2.3 Gy/fr) with 
Tomotherapy to the tumor and regional lymph-nodes (PTV) 
defined on CT/MRI imaging. After 9 fr, CT and MRI were 
repeated for the planning of the adaptive phase: PTVadapt was 
generated by adding a 5mm margin to the residual tumour 
visible on MRI images. In the last 6 fr, a boost of 3.0 Gy/fr 
(total dose: 45.6 Gy in 18 fr) was delivered to PTVadapt while 
concomitantly delivering 2.3 Gy/fr to PTV outside PTVadapt. 
Data regarding acute toxicity and outcome were analyzed. 
Results: From September 2009 to April 2014, 50 pts 
completed the preoperative treatment and were evaluable. 
No G4 toxicity occurred: the G3 toxicity was gastrointestinal 
only: diarrhoea in 9/50 pts (18%), and proctitis in 2/50 (4%). 
Diarrhoea started before the adaptive phase in all cases and 
all affected patients were women. Two pts achieved 
complete response (cCR) and refused surgery, 1 pt was lost, 1 
pt had early distant progression. Forty-six pts underwent 
surgery (43 R0, 3 R1): thirteen pts (28 %) had pathological 
complete response (pCR); 22/46 (47%) showed TRG3 
response: 13/46 (28%) and 6/46 (13%) had ≤5%, and 6-10% 
residual viable cells, respectively. Regarding the two patients 
with cCR who refused surgery, one is still cCR after 54 
months while the other had local relapse and underwent 
transanal resection 1 year after treatment. Concerning 
treatment feasibility, two pts interrupted radiotherapy after 
7 and 13 fr respectively, the remaining pts (48/50=96%) 
completed the treatment, and the median duration of RT was 
25 days (22-36 days). 43/50 pts (86%) and 40/50 pts (80%) 
received the full dose of oxaliplatin and FU, respectively: 14% 
of pts received moderately reduced doses (60%-90%), and 
only two pts (4%) received less than 60% of the planned dose.  
Conclusions: This study confirms that adaptive boost strategy 
is feasible with an acceptable G3 toxicity rate and a very 
encouraging tumour response rate. The results suggest that 
there should still be room for further dose escalation with 
the aim of increasing pCR and/or cCR rates. 
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Purpose/Objective: In 2011, we build a dedicated 
Brachytherapy (BT) treatment suite, equipped with an HDR 
afterloader and a 1.5 T MR scanner. In this study, we 
evaluated in which way the MR scanner influences the 
position verification of applicator and organs at risk (OAR) 
and induces adaptive interventions during the process of 
brachytherapy for cervical cancer patients. 
Materials and Methods: We collected the data from 16 
patients (32 applications), treated with the MR compatible 
Utrecht tandem/ovoid intracavitary/interstitial applicator 
(Elekta Brachytherapy, The Netherlands) during the last year. 
The brachytherapy treatment schedule consisted of two 
applications and delivery of two HDR fractions each (7 
Gy/fr). Applicator insertion, repeated MR imaging and HDR 
dose delivery were performed in our treatment room 
equipped with a 1.5 T MRI scanner and a conventional 
afterloader (Elekta Brachytherapy, The Netherlands). 
Multiple MR scans during the process of BT were taken (see 
table). For this analysis we evaluated how often we actually 
performed direct adaptive interventions aiming at the 
reduction of uncertainties in dose delivery. Before the first 
applicator placement, MR images were taken to evaluate 
tumor extension and the need for needles. If needles were 
used, short sequence MR scans could be taken directly after 
the insertion to verify applicator and needle placement and 
allow adaptation before taking the definitive scans for 
treatment planning. Prior to dose delivery, MR scanning was 
repeated for position verification of the applicator parts in 
relation to the tumor and in order to detect anatomical 
changes of the OAR's. Adaptive interventions included 
repositioning of interstitial needles, insertion of rectal tubes 
to deflate gas or to change the position of the rectum, and 
variations in bladder filling mainly to reduce bowel dose. 
 
Results: In 18 of 25 applications with interstitial needles 
short sequence MR scans were taken to check needle position 
resulting in repositioning in 3 cases. In 10 of the 16 patients 
we did interventions with respect to the OAR's, 4 times for 
bladder and 7 times for rectum. Moreover, we better learned 
to individualize the use of rectal probes and bladder fillings: 
One year ago we left the rectal probe in place during 
irradiation but we discovered it not only deflated gas but also 
could displace the rectum position. In some cases it brought 
the rectum closer into the high dose areas. This resulted in a 
change of procedure. Nowadays we usually insert the probe 
for deflation and then remove it before scanning and 
irradiation. 
Conclusions: Having a combined 1,5 T MRI/HDR treatment 
room makes it possible to perform position verifications and 
adaptive interventions that helps to reduce uncertainties in 
brachytherapy and to deliver the prescribed dose as accurate 
as possible according to plan.  
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Purpose/Objective: Volumetric modulated arc therapy 
(VMAT) was demonstrated to be feasible for radiosurgical 
treatment of multiple cranial metastases (MCM). The pitch 
and roll inclusions of 107 brain patients treated in our 
institute on the PerfectPitch™ 6 degrees of freedom couch 
revealed 65.5% and 31.8% had pitch and/or roll 
compensations greater than 1° and 2°. We have investigated 
the dosimetric consequences of inaccurate pitch and roll 
